10 August 2018
Visiongain has launched a new pharma report Global Treatment for Neglected Tropical Disease Market 2017-2027: Malaria, Dengue, Leishmaniasis, Schistosomiasis, Lymphatic Filariasis, Chagas Disease
According to the Centers for Disease Control and Prevention (CDC), one hundred percent of low-income countries are affected by at least five neglected tropical diseases simultaneously. Worldwide, 149 countries and territories are affected by at least one neglected tropical disease (NTD). The disease burden, however, is not restricted to these areas since vectors and parasites can often spread to other regions via travellers or cargo. Every year, malaria alone results in one to three million deaths out of approximately half a billion cases, while many more go undetected or undiagnosed.
The lead analyst of the report commented “The treatment for neglected tropical disease market is set to experience considerable growth over the next decade. The main growth drivers include, rising awareness towards neglected tropical disease, increasing prevalence of neglected disease such as malaria and dengue as well as increasing governments’ initiatives.
There are still gaps that need to be met. Improved diagnostics for neglected tropical diseases for example, are essential for guiding treatment strategies at different thresholds of control, interruption of transmission, elimination and post-elimination surveillance.”
Leading companies featured in the report include Pfizer, Inc., Bayer, GlaxoSmithKline plc, Merck & Co., Inc., Novartis International AG, Takeda Pharmaceutical Company Ltd, Sanofi S.A. and Eisai Co., Ltd.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
. The growth of this market is majorly driven by increasing sales of temperature sensitive pharmaceutical products, longer life expectancy and rising geriatric population are some of the prominent factors.
16 September 2020
Visiongain forecasts a continuing growth in global market, submarket and product sales as human vaccines drive pharmaceutical business sales. New key players and technological progress will enter the industry, leading to an increase in the market size of the world market for human vaccines in general.
14 September 2020
The global ophthalmic ultrasound systems market is driven by factors such as the increasing prevalence of ocular disorders and diseases, adoption of novel ophthalmic technologies, rising focus on research & development, and growing health awareness amongst the population.
09 September 2020
The current COVID-19 pandemic is anticipated to have a minor impact on the overall outsourcing business outlook for global drug discovery. Also, significant growth during the COVID-19 pandemic is expected to be seen in the outsourcing of drugs and medicines needed to treat COVID-19 infections.